OBJECTIVE: Hypertensive diseases of pregnancy (HDP), including gestational hypertension and preeclampsia, are associated with increased risk for stillbirth. Patients with HDP may be admitted antenatally and then discharged with increased surveillance. For women with HDP at delivery, we sought to determine if preceding antenatal admission for HDP was associated with increased risk of stillbirth. STUDY DESIGN: This study used the 2010-2014 Nationwide Readmission Database. Deliveries hospitalizations with HDP occurring October to December each year were analyzed. We defined an antenatal admission with HDP as the primary diagnosis occurred within 9 months preceding each delivery. Our primary outcomes were stillbirth and stillbirth with placental abruption during delivery hospitalization. Subgroup analyses were conducted among patients admitted antenatally for HDP with primary predictors of number of admissions and cumulative antepartum length of stay. Log linear regression models including demographic and hospital factors were fit to characterize the adjusted effect of antepartum HDP admission on stillbirth. RESULTS: 3.9 million deliveries occurred in this time period, with 319,105 (8.2%) HDP deliveries occurred in this time period, (overall 8.2%), 0.8% with stillbirth (n¼2,464), and 0.2% (n¼553) with stillbirth and abruption. 3.2% (n¼10,297) required antepartum admission for HDP. Among women with HDP, antepartum HDP admission was associated with higher risks of stillbirth and stillbirth/ abruption (1.2% vs. 0.8%, 0.3% vs. 0.2%, respectively, p<0.01). In adjusted analysis, patients with HDP antepartum admissions were at increased risk of stillbirth/abruption (RR¼1.52, 95% CI:
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.